서브메뉴
검색
Advancing Cationic Micelle Lipid Nanoparticles and Extracellular Vesicles as Vectors for Hydrophobic Anticancer Drug Delivery
Advancing Cationic Micelle Lipid Nanoparticles and Extracellular Vesicles as Vectors for Hydrophobic Anticancer Drug Delivery
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202103622
- ISBN
- 9798291542330
- DDC
- 574.191
- 저자명
- Fisher, William.
- 서명/저자
- Advancing Cationic Micelle Lipid Nanoparticles and Extracellular Vesicles as Vectors for Hydrophobic Anticancer Drug Delivery
- 발행사항
- [Sl] : University of California, Santa Barbara, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 274 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 87-02, Section: B.
- 주기사항
- Advisor: Safinya, Cyrus R.
- 학위논문주기
- Thesis (Ph.D.)--University of California, Santa Barbara, 2025.
- 초록/해제
- 요약Lipid nanoparticles are promising delivery vehicles for hydrophobic anti-cancer drugs that enable targeted accumulation of drug at specific tissues and reduced systemic side effects. However, their clinical success is limited by challenges in drug loading, targeting in vivo, and endosomal entrapment. Developing next generation lipid nanoparticles that overcome these challenges is critical to realize their full potential to transform cancer chemotherapy.This doctoral work establishes a protocol for isolation of extracellular vesicles (EVs) and expands their ability to load the hydrophobic cancer chemotherapy drug paclitaxel (PTX) for drug delivery applications. EVs are nanoscale, cell-secreted vesicles that facilitate intercellular communication. Exosomes are a subset of EVs with 30 to 150 nm diameters that have high potential as drug delivery vectors because they show low immunogenicity and cell-specific cytosolic delivery of their contents. A serial centrifugation and differential ultracentrifugation protocol was used to isolate vesicles from prostate and melanoma cancer cells that had protein enrichment, diameters, and high membrane rigidity consistent with exosomes. Despite achieving high yields of EVs for both cell types, we observed inefficient loading of PTX in isolated EVs, which restricts their therapeutic application. To overcome this, we adapted a Forster resonance energy transfer (FRET) based lipid mixing assay to study methods for fusion of EVs with synthetic, PTX-loaded liposomes to create hybrid PTX delivery vesicles. We discovered that acidic conditions enhanced the fusion of EVs with bare synthetic liposomes while avoiding contaminating depletants and preserving EV membrane proteins. Remarkably, acidic conditions also induced clustering of EVs with themselves. These findings reveal a previously unexplored protein-lipid or lipid-lipid component to EV content release and enables minimally perturbative modification of EV contents towards a hybrid drug delivery vesicle.In parallel, we investigated the capacity of cationic liposomes (CLs) and cationic lipid nanoparticles (CLNPs) with novel membrane lipids and micellar structures to load and deliver PTX to cancer cells in vitro and in vivo. We found that lipid tails containing two cis double bonds enhanced the PTX loading of CLs by nearly 3-fold over conventional single cis double bond tails used in clinical stage CLs currently (e.g. EndoTAG-1TM), while maintaining or enhancing their cytotoxic efficacy against cancer cells. With respect to lipid headgroups, prior work revealed that incorporation of polyethylene glycol (PEG)-conjugated lipids (PEGylation) above a threshold membrane content drives the formation of disc-shaped micelles (nanodiscs), a novel structure for CLNPs with fluid-phase membranes, and improves cellular uptake and cytotoxic efficacy of CLs. Building on this, we demonstrated that CLs with PEG-lipid contents above this threshold show 10 to 35-fold greater tumor accumulation than those with sub-threshold PEG-lipid contents in vivo. This led us to explore using the novel multivalent lipid MVL5 in PTX-loaded CLNPs following the observation that CLNPs containing 50 mol% MVL5 form particle populations consisting of entirely nanodiscs, with rod and spherical micelles forming at 75 mol% or greater MVL5. Unexpectedly, a nearly 2-fold improvement in PTX solubility was observed for micellar MVL5 CLNPs over CLs based on EndoTAG-1TM containing the univalent cationic lipid DOTAP. This enhanced solubility translated to improved cytotoxic efficacy at high PTX content in vitro, with PEGylation driving further improvement. Finally, we found that steric stabilization of sub-200 nm diameter particles by PEGylation significantly improves MVL5 CLNP cell uptake and penetration depth. This supports a model where the rate limiting steps of PTX delivery by CLNPs are diffusion of endocytic vesicles containing CLNPs across the actin mesh near the cell surface, combined with hopping of PTX from endosomal vesicle membranes to nearby microtubules. By identifying and enhancing physicochemical properties of CLNPs critical to their performance as PTX delivery vehicles, these findings provide actionable steps which would improve the cost, safety, and efficacy of CLNPs as hydrophobic drug delivery vehicles in clinical applications.
- 일반주제명
- Biophysics
- 일반주제명
- Bioengineering
- 일반주제명
- Pharmaceutical sciences
- 일반주제명
- Nanotechnology
- 키워드
- Cancer
- 키워드
- Cationic
- 키워드
- Drug delivery
- 키워드
- Paclitaxel
- 기타저자
- University of California, Santa Barbara Biomolecular Science and Engineering
- 기본자료저록
- Dissertations Abstracts International. 87-02B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017357954
■00520260202103622
■006m o d
■007cr#unu||||||||
■020 ▼a9798291542330
■035 ▼a(MiAaPQ)AAI32045797
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a574.191
■1001 ▼aFisher, William.
■24510▼aAdvancing Cationic Micelle Lipid Nanoparticles and Extracellular Vesicles as Vectors for Hydrophobic Anticancer Drug Delivery
■260 ▼a[Sl]▼bUniversity of California, Santa Barbara▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a274 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 87-02, Section: B.
■500 ▼aAdvisor: Safinya, Cyrus R.
■5021 ▼aThesis (Ph.D.)--University of California, Santa Barbara, 2025.
■520 ▼aLipid nanoparticles are promising delivery vehicles for hydrophobic anti-cancer drugs that enable targeted accumulation of drug at specific tissues and reduced systemic side effects. However, their clinical success is limited by challenges in drug loading, targeting in vivo, and endosomal entrapment. Developing next generation lipid nanoparticles that overcome these challenges is critical to realize their full potential to transform cancer chemotherapy.This doctoral work establishes a protocol for isolation of extracellular vesicles (EVs) and expands their ability to load the hydrophobic cancer chemotherapy drug paclitaxel (PTX) for drug delivery applications. EVs are nanoscale, cell-secreted vesicles that facilitate intercellular communication. Exosomes are a subset of EVs with 30 to 150 nm diameters that have high potential as drug delivery vectors because they show low immunogenicity and cell-specific cytosolic delivery of their contents. A serial centrifugation and differential ultracentrifugation protocol was used to isolate vesicles from prostate and melanoma cancer cells that had protein enrichment, diameters, and high membrane rigidity consistent with exosomes. Despite achieving high yields of EVs for both cell types, we observed inefficient loading of PTX in isolated EVs, which restricts their therapeutic application. To overcome this, we adapted a Forster resonance energy transfer (FRET) based lipid mixing assay to study methods for fusion of EVs with synthetic, PTX-loaded liposomes to create hybrid PTX delivery vesicles. We discovered that acidic conditions enhanced the fusion of EVs with bare synthetic liposomes while avoiding contaminating depletants and preserving EV membrane proteins. Remarkably, acidic conditions also induced clustering of EVs with themselves. These findings reveal a previously unexplored protein-lipid or lipid-lipid component to EV content release and enables minimally perturbative modification of EV contents towards a hybrid drug delivery vesicle.In parallel, we investigated the capacity of cationic liposomes (CLs) and cationic lipid nanoparticles (CLNPs) with novel membrane lipids and micellar structures to load and deliver PTX to cancer cells in vitro and in vivo. We found that lipid tails containing two cis double bonds enhanced the PTX loading of CLs by nearly 3-fold over conventional single cis double bond tails used in clinical stage CLs currently (e.g. EndoTAG-1TM), while maintaining or enhancing their cytotoxic efficacy against cancer cells. With respect to lipid headgroups, prior work revealed that incorporation of polyethylene glycol (PEG)-conjugated lipids (PEGylation) above a threshold membrane content drives the formation of disc-shaped micelles (nanodiscs), a novel structure for CLNPs with fluid-phase membranes, and improves cellular uptake and cytotoxic efficacy of CLs. Building on this, we demonstrated that CLs with PEG-lipid contents above this threshold show 10 to 35-fold greater tumor accumulation than those with sub-threshold PEG-lipid contents in vivo. This led us to explore using the novel multivalent lipid MVL5 in PTX-loaded CLNPs following the observation that CLNPs containing 50 mol% MVL5 form particle populations consisting of entirely nanodiscs, with rod and spherical micelles forming at 75 mol% or greater MVL5. Unexpectedly, a nearly 2-fold improvement in PTX solubility was observed for micellar MVL5 CLNPs over CLs based on EndoTAG-1TM containing the univalent cationic lipid DOTAP. This enhanced solubility translated to improved cytotoxic efficacy at high PTX content in vitro, with PEGylation driving further improvement. Finally, we found that steric stabilization of sub-200 nm diameter particles by PEGylation significantly improves MVL5 CLNP cell uptake and penetration depth. This supports a model where the rate limiting steps of PTX delivery by CLNPs are diffusion of endocytic vesicles containing CLNPs across the actin mesh near the cell surface, combined with hopping of PTX from endosomal vesicle membranes to nearby microtubules. By identifying and enhancing physicochemical properties of CLNPs critical to their performance as PTX delivery vehicles, these findings provide actionable steps which would improve the cost, safety, and efficacy of CLNPs as hydrophobic drug delivery vehicles in clinical applications.
■590 ▼aSchool code: 0035.
■650 4▼aBiophysics
■650 4▼aBioengineering
■650 4▼aPharmaceutical sciences
■650 4▼aNanotechnology
■653 ▼aCancer
■653 ▼aCationic
■653 ▼aDrug delivery
■653 ▼aExtracellular vesicles
■653 ▼aLipid nanoparticles
■653 ▼aPaclitaxel
■690 ▼a0786
■690 ▼a0202
■690 ▼a0572
■690 ▼a0652
■71020▼aUniversity of California, Santa Barbara▼bBiomolecular Science and Engineering.
■7730 ▼tDissertations Abstracts International▼g87-02B.
■790 ▼a0035
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17357954▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.


